logo
Longevity doctor reveals the best diets for healthy aging — and the change to make at 65

Longevity doctor reveals the best diets for healthy aging — and the change to make at 65

Yahoo16 hours ago

Your love of steak could make you prematurely meat your maker.
While protein is essential for muscle maintenance and overall health, eating too much protein — especially at a certain age — could be shaving years off your life.
'Animal proteins are rich in arginine, leucine and contain specific sequences of amino acids that stimulate IGF-1 secretion, whereas an equivalent quantity of plant-based proteins are less likely to trigger the same amount of IGF-1,' Dr. Joseph Antoun, CEO of the longevity company L-Nutra, told The Post.
IGF-1 is a hormone, primarily produced in the liver, that plays a crucial role in promoting growth and regulating metabolism.
It's essential for building muscle when you're young and especially when you're older, as muscle loss often accelerates over 60. Because IGF-1 levels tend to decline in adulthood, it's important to maintain a healthy range to support well-being.
'Before age 30, it is considered healthy to consume certain amounts of meat in a plant-based diet,' Antoun said.
'The same applies after the age of 65, when the body's food absorption capability begins to decrease and muscle becomes an essential organ for longevity.'
If you're between those two numbers — you should be eyeballing the salad bar more than the steak buffet.
'Between the ages of 30-65, consumption of mainly plant-based sources of protein is recommended,' he said.
'The mid-life period is the age of disease formation and is when the speed and quality of aging mostly determines our lifespan.'
If you're looking to live to 100, Antoun is a proponent of the Longevity Diet, which leans heavily on plant-based proteins like beans, legumes, nuts and seeds.
'The Longevity Diet emphasizes plant-based protein consumption to support lean muscle mass and reduce inflammation, which are important for both heart and metabolic health,' he said.
Plant-based diets such as the pescatarian, Mediterranean and flexatarian plans are also linked to healthy aging, as is the vegan diet, although some adjustments should be made.
'A pure vegan diet is also correlated with longevity, but it needs to be supplemented with protein — especially at early and late stages of life,' he said.
And if you've ever wondered why bodybuilders look amazing when they're young, only to seem as if they stepped into a time machine once they reach their twilight years — it's because getting ripped has ripped them of their ageless appearance.
'Animal-based diets stimulate IGF-1 and therefore help a consumer look good and muscular in the short term, which many food companies market as a sign of health and strength — when in fact, the body is in 'accelerated bio-age mode,' which leads to a shorter lifespan,' he said.
'Bodybuilders, for example, look great in the short term, but end up looking far older than their real age in their 50s and 60s.'
Finally, when it comes to longevity, Orwell had it right. All animals are equal, but some are more equal than others.
'Not all animal proteins are the same,' Antoun said.
'Red meat, chicken and fish contain different percentages of leucine and arginine,' he added, referencing two amino acids that play vital roles in muscle growth. 'Red meat is also high in saturated fats, while fish contains healthier, unsaturated fats.'
In short: sticking to chickpeas while you're middle-aged means you'll be able to really enjoy that nice, juicy burger once you're in retirement.
Eat to live — don't lift to eat.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

TELO Rises on Promising Telomir-1 Preclinical Results
TELO Rises on Promising Telomir-1 Preclinical Results

Yahoo

time9 hours ago

  • Yahoo

TELO Rises on Promising Telomir-1 Preclinical Results

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is among the 10 Best Growth Stocks Under $100 to Buy Now. On Wednesday, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) revealed that its leading product, Telomir-1, showcased a marked improvement in the neurological, liver, and kidney symptoms observed in a preclinical animal model of Wilson's disease. In a zebrafish model mimicking Wilson's disease, the drug showed substantial dose-dependent improvements, including a decrease in tremors, a normal swimming behavior, and a 50% reduction in copper accumulation in liver tissue. It also led to better liver and kidney histopathology while restoring key biomarkers. As Dr. Angel, Chief Scientific Advisor at Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), mentioned, 'These recent findings establish Telomir-1 as a potent disease-modifying compound in a clinically relevant model of Wilson's disease.' A biopharmaceutical research laboratory filled with scientists, illuminated by the glow of their equipment. With a market capitalization of $59.079 million, the company is also positioning its drug through IND-enabling studies, with plans to submit its first IND for a rare disease by the year's end, followed by human trials in the first half of the next year. Analysts have set a price target of $15.50 for Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), implying an upside of a whopping 688%. These well-structured plans highlight the company's position to lead the global market in the years ahead. Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a pre-clinical stage biopharmaceutical company that emphasizes the reversal of oxidative stress, cellular protection, and regulatory mechanisms. Incorporated in 2021, this Florida-based company is designing and developing products to address the causes of rare diseases. While we acknowledge the potential of TELO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

TELO Rises on Promising Telomir-1 Preclinical Results
TELO Rises on Promising Telomir-1 Preclinical Results

Yahoo

time12 hours ago

  • Yahoo

TELO Rises on Promising Telomir-1 Preclinical Results

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is among the 10 Best Growth Stocks Under $100 to Buy Now. On Wednesday, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) revealed that its leading product, Telomir-1, showcased a marked improvement in the neurological, liver, and kidney symptoms observed in a preclinical animal model of Wilson's disease. In a zebrafish model mimicking Wilson's disease, the drug showed substantial dose-dependent improvements, including a decrease in tremors, a normal swimming behavior, and a 50% reduction in copper accumulation in liver tissue. It also led to better liver and kidney histopathology while restoring key biomarkers. As Dr. Angel, Chief Scientific Advisor at Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), mentioned, 'These recent findings establish Telomir-1 as a potent disease-modifying compound in a clinically relevant model of Wilson's disease.' A biopharmaceutical research laboratory filled with scientists, illuminated by the glow of their equipment. With a market capitalization of $59.079 million, the company is also positioning its drug through IND-enabling studies, with plans to submit its first IND for a rare disease by the year's end, followed by human trials in the first half of the next year. Analysts have set a price target of $15.50 for Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), implying an upside of a whopping 688%. These well-structured plans highlight the company's position to lead the global market in the years ahead. Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a pre-clinical stage biopharmaceutical company that emphasizes the reversal of oxidative stress, cellular protection, and regulatory mechanisms. Incorporated in 2021, this Florida-based company is designing and developing products to address the causes of rare diseases. While we acknowledge the potential of TELO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Weight-Loss Medications Less Effective for People in the 'Real World,' New Study Finds
Weight-Loss Medications Less Effective for People in the 'Real World,' New Study Finds

Yahoo

time14 hours ago

  • Yahoo

Weight-Loss Medications Less Effective for People in the 'Real World,' New Study Finds

A new study analyzed patients who used GLP-1 medications in a real-world setting Researchers found that participants lost less weight compared to use in clinical trials They believe discontinuation rates are due to high out-of-pocket costs, issues with insurance coverage, side effects and supply shortagesWeight-loss medications like Ozempic and Mounjaro are not as effective in a 'real-world' setting, according to a new study. The study — published June 10 in the Obesity Journal — analyzed nearly 8,000 patients who were classified as having severe obesity. Between 2021 and 2023, they were treated with semaglutide or tirzepatide, injectable GLP-1 medications, in a real-world setting. GLP-1 is short for glucagon-like peptide-1 receptor agonists, which work in the brain to impact satiety. Semaglutide is sold under brand names Ozempic and Wegovy, and tirzepatide is sold under brand names Mounjaro and Zepbound. In a follow-up study, which ended in December 2024, researchers grouped patients who discontinued their obesity medications into those who discontinued early (within 3 months) and late (within 3-12 months). Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer​​, from celebrity news to compelling human interest stories. is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! They found that more than 20% of patients discontinued their medications early and 32% discontinued their medications late. Additionally, more than 80% of patients were on lower maintenance dosages of their medications. After a year of treatment, the average weight loss was 3.6% for those who discontinued their treatment early, compared to 6.8% for those who discontinued their treatment late. Those who continued treatment lost about 12% of their body weight. During clinical trials for the GLP-1s, patients lost about 15% to 20% of their body weight. 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,' Dr. Hamlet Gasoyan, Cleveland Clinic researcher and lead author of the study, said in a statement. The study notes that discontinuation rates during real-world use were higher than those in a clinical trial setting due to high out-of-pocket costs, issues with insurance coverage, side effects and supply shortages. Read the original article on People

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store